Dr
Andrew
Wells

Partner & Head of Chemistry

Manchester Office

Chemistry

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 752 507 1499
Email. [email protected]

Experience

Andrew’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices. Outside of the pharmaceutical field, Andrew’s practice encompasses agrochemicals, polymer chemistry, petroleum additives, catalytic compositions, separation chemistry, adhesive technologies and biosensors.

Andrew acts for a diverse range of clients, including international corporations, universities, start-up companies and associate patent attorney firms based outside of the UK.

He commenced his patent career in private practice before joining the in-house patent department of a major multi-national pharmaceutical company in June 2004. As an in-house attorney, Andrew was responsible for the patent portfolios relating to a number of high priority drug development projects, as well as conducting IP due diligence evaluations to support in-licensing activities. Andrew returned to private practice in November 2008 when he joined the Manchester office of HGF as a Partner.

Andrew draws on both his private practice and in-house experience to provide commercially-focused advice to his clients in relation to all patent matters, including patent portfolio management, enforcing patent rights, challenging third party patent rights, providing infringement and validity opinions, and conducting due diligence evaluations to support licensing and acquisition deals. Andrew also has considerable experience in representing clients in opposition and appeal proceedings at the European Patent Office.

Qualifications

Patent Attorney

Chartered (UK)
European


PHD

The development and evaluation of microparticulate formulations for DNA immunisation

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate in Intellectual Property Law

OTHER

BPharm

Recognition

IAM Strategy 300 - Leading IP Strategists

Andrew is listed in the IAM Strategy 300 as a leading IP strategist

View recognition online

IAM Patent 1000

Andrew is listed in the IAM Patent 1000 as a leading IP attorney in his field.

View recognition online

MIP Star

Andrew is listed as a MIP Star.

View recognition online

Publications

IAM Patent 1000 2022

View publication online

IAM Strategy 300 2021

View publication online

Drug repurposing: progress, challenges and recommendations - Nature Medicine article on Drug Repurposing

View publication online

Conferences: 2021

October 7th 2021

The Business of Science Conference 2021

Attended

Event details

CSR

Andrew mentors and contributes to the professional training of Trainee Patent Attorneys within HGF, as well as mentoring and training of IP and technology transfer professionals in other organisations.

Related News

Event - 21st-22nd September 2022

Medical Technology Ireland 2022

Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …

Event details

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.